Growth Metrics

Resmed (RMD) Cash from Financing Activities (2016 - 2025)

Resmed's Cash from Financing Activities history spans 17 years, with the latest figure at -$258.3 million for Q4 2025.

  • For Q4 2025, Cash from Financing Activities fell 75.11% year-over-year to -$258.3 million; the TTM value through Dec 2025 reached -$796.6 million, up 22.47%, while the annual FY2025 figure was -$606.3 million, 45.84% up from the prior year.
  • Cash from Financing Activities reached -$258.3 million in Q4 2025 per RMD's latest filing, down from -$230.3 million in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $932.9 million in Q4 2022 to a low of -$393.3 million in Q2 2024.
  • Average Cash from Financing Activities over 5 years is -$109.6 million, with a median of -$154.8 million recorded in 2021.
  • Peak YoY movement for Cash from Financing Activities: plummeted 961.99% in 2021, then soared 527.99% in 2022.
  • A 5-year view of Cash from Financing Activities shows it stood at -$218.0 million in 2021, then skyrocketed by 527.99% to $932.9 million in 2022, then plummeted by 125.61% to -$239.0 million in 2023, then soared by 38.26% to -$147.5 million in 2024, then tumbled by 75.11% to -$258.3 million in 2025.
  • Per Business Quant, the three most recent readings for RMD's Cash from Financing Activities are -$258.3 million (Q4 2025), -$230.3 million (Q3 2025), and -$163.9 million (Q2 2025).